anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A composition for intracellular delivery of a chemical agent into a T cell comprises a receptor-binding and endocytosis-inducing ligand and a chemical agent coupled to a water soluble polymer. The ligand binds to a receptor on T  lymphocytes and elicits endocytosis of the composition. The composition also includes a spacer for coupling the chemical agent and the ligand to the polymer. Chemical agents can include cytotoxins, transforming nucleic acids, gene regulators, labels, antigens, drugs, and the like. A preferred water soluble polymer is a copolymer of N-(2-hydroxypropyl)methacrylamide (HPMA).  The composition can further comprise a carrier such as a water soluble polymer, liposome, or particulate. Methods of using these compositions for delivering a chemical agent in vivo or in vitro are also disclosed.
A phase Ia clinical trial of the study of 24-valent Pneumococcal Conjugate Vaccine (PCV24) developed by Sinovac Life Science Co., Ltd (Sinovac) will be conducted in Chinese children aged 2-17 years. The trial is a randomized, double-blind, controlled combined with open-label study. The objective of this study is to evaluate the safety and immunogenicity of PCV24 manufactured by Sinovac Life Science Co., Ltd. The active control vaccine for participants aged 2-5 years is the Prevenar13® manufactured by Pfizer.

A total of at least 114 participants will be enrolled, including 24 children aged 6-17 years and 90 children aged 2-5 years. Children aged 6-17 years will receive PCV24 formulation 1 and PCV24 formulation 2 in a 1:1 ratio. Children aged 2-5 years will receive PCV24 formulation 1, PCV24 formulation 2 and Prevenar13® in a 1:1:1 ratio.
The present invention relates to a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding at least one of (i) a tumor antigen, (ii) a fragment of a tumor antigen, and (iii) a variant of (i) or (ii). The present invention further relates to a polynucleotide encoding said recombinant virus of the family Paramyxoviridae and to a host cell comprising said recombinant virus of the family Paramyxoviridae and/or said polynucleotide encoding said recombinant virus of the family Paramyxoviridae. More over, the present invention relates to a method for activating immune cells with antitumor activity in a sample comprising cancer cells and to further means, methods, and uses related to the present invention. cm 0 e- Ua -jE E E)V rC. C4 (0 .0 CL. r- L. IC (0 ~ m 0. 4- 0 LL _ o> o 0~ x < Z (Iw~njo) Z0IR )POOW 01 OAlleIOJ Apliqe*A 1100
Doxorubicin (DOX; also known as adriamycin) serves as a crucial antineoplastic agent in cancer treatment; however, its clinical utility is hampered by its' intrinsic cardiotoxicity. Although most DOX biotransformation occurs in the liver, a comprehensive understanding of the impact of DOX biotransformation and its' metabolites on its induced cardiotoxicity remains to be fully elucidated. This study aimed to explore the role of biotransformation and DOX's main metabolites in its induced cardiotoxicity in human differentiated cardiac AC16 cells. A key discovery from our study is that modulating metabolism had minimal effects on DOX-induced cytotoxicity: even so, metyrapone (a non-specific inhibitor of cytochrome P450) increased DOX-induced cytotoxicity at 2 µM, while diallyl sulphide (a CYP2E1 inhibitor) decreased the 1 µM DOX-triggered cytotoxicity. Then, the toxicity of the main DOX metabolites, doxorubicinol [(DOXol, 0.5 to 10 µM), doxorubicinone (DOXone, 1 to 10 µM), and 7-deoxydoxorubicinone (7-DeoxyDOX, 1 to 10 µM)] was compared to DOX (0.5 to 10 µM) following a 48-h exposure. All metabolites evaluated, DOXol, DOXone, and 7-DeoxyDOX caused mitochondrial dysfunction in differentiated AC16 cells, but only at 2 µM. In contrast, DOX elicited comparable cytotoxicity, but at half the concentration. Similarly, all metabolites, except 7-DeoxyDOX impacted on lysosomal ability to uptake neutral red. Therefore, the present study showed that the modulation of DOX metabolism demonstrated minimal impact on its cytotoxicity, with the main metabolites exhibiting lower toxicity to AC16 cardiac cells compared to DOX. In conclusion, our findings suggest that metabolism may not be a pivotal factor in mediating DOX's cardiotoxic effects.
Participants entering from the multiple ascending dose (MAD) part of study NN7769-4513. In part 1, participants will receive Mim8 prophylaxis (PPX) once every two weeks (Q2W) with subcutaneous (s.c.) administration using enhanced cartridge for 26 weeks. In part 2, participants will receive Mim8 PPX once-weekly (QW), Q2W or once-monthly (QM) with s.c. administration using enhanced cartridge or DV3407 pen-injector once it is approved.
Subjects with a High Baseline CRP will receive Minocycline. During the first week, subjects will receive one 100 mg capsule daily. On weeks 2-12, the subject will receive two 100 mg capsules at bedtime. The blinded psychiatrist (blinded to CRP status) will be allowed to reduce the dose if the subject complains of any side effect. Pending tolerability, the subject will have 200 mg per day.
The esophagus is rarely affected by Mycobacterium A 75-y-old man presented with upper abdominal pain and significant weight loss for 2 mo. Contrast-enhanced CT, upper gastrointestinal endoscopy, and abdominal vessel angiography gave normal results. To clarify the facts, 18F-FDG PET/CT was performed, revealing an 18F-FDG-avid lesion in the posterior wall of the lower thoracic esophagus. On endoscopic ultrasound-guided fine-needle aspiration of this lesion, puslike material was released. On microscopic examination, acid-fast bacilli were noted. The patient then began receiving standard antitubercular therapy.
BACKGROUND: Diagnostic imaging using CT enterography, magnetic resonance enterography, and intestinal ultrasound are important tools in evaluating stricturing Crohn's disease. Definitions of strictures have been developed for CT enterography and magnetic resonance enterography. However, expert recommendations for definitions and treatment response of strictures on intestinal ultrasound are not available. The aim of this study was to standardise definitions, diagnosis, and treatment response criteria in small bowel stricturing Crohn's disease on intestinal ultrasound.
METHODS: Using modified RAND-University of California Los Angeles Appropriateness Method, a diverse expert panel of 13 gastroenterologists, seven radiologists, and two patient representatives was assembled. A total of 466 statements on definitions and response to therapy of stricturing Crohn's disease on intestinal ultrasound were generated from a systematic review and from expert opinion, with subsequent rating for appropriateness. Two rounds of voting with an interposed survey result discussion were performed. Statements were classified as inappropriate, uncertain, or appropriate based on the median panel rating and degree of disagreement. Appropriateness was rated using a nine-point Likert scale (1 being inappropriate, 9 being highly appropriate).
FINDINGS: A naive or anastomotic small bowel Crohn's disease stricture on intestinal ultrasound is defined by the combination of bowel wall thickening, luminal narrowing, and pre-stenotic dilation. Bowel wall thickness is defined as being more than 3 mm. Luminal narrowing is defined as either a luminal diameter reduction of more than 50% in the narrowest area and relative to a normal adjacent bowel loop, or a luminal diameter of less than 1 cm. Pre-stenotic dilation is defined as more than 2·5 cm or an increase in bowel diameter relative to a normal adjacent bowel loop. Definitions for grading hyperaemia, inflammatory fat, wall stratification, intestinal ultrasound machine technical parameters, and image acquisition were also devised. Treatment response of strictures was defined as reduction in stricture length, bowel wall thickening, luminal narrowing, pre-stenotic dilation, and motility abnormalities.
INTERPRETATION: To our knowledge, this is the first intestinal ultrasound appropriateness rating exercise conducted for defining, diagnosing, and measuring response to therapy in small bowel stricturing Crohn's disease and informs future clinical use and intestinal ultrasound index development for clinical trials.
FUNDING: Leona M and Harry B Helmsley Charitable Trust.
Hot flashes affect approximately 75% of postmenopausal women. Although hormone replacement therapy (HRT) is highly effective in reducing hot flashes, long-term HRT is associated with increased rates of breast cancer and heart disease. Safe, effective, and well-tolerated hot flash therapies are needed. The amino acids L-methionine and L-isoleucine have produced reductions in hot flash frequency. However, long-term L-methionine therapy may increase cardiovascular risks. This study will evaluate the short-term effects of L-isoleucine therapy. Data from this study will be used to conduct long-term studies in the future.

Participants in this study will be randomly assigned to receive one of two different L-isoleucine doses for 2 weeks. Clinic visits will be made at baseline, Week 1, and Week 10. Participants will record the frequency and severity of their hot flashes in a diary.
The invention discloses a rose toner. The rose toner comprises, by mass, 10 parts of rose hydrolat, 1 part of sandalwood essential oil and 1 part of palmarosa essential oil. The rose hydrolat is prepared by mixing newly-plucked fresh rose with slat under stirring so as to seal up fragrance, then putting the fresh rose into a distillation retort and carrying out oil-water separation; and the rose hydrolat is soluble in water and capable of supplementing water, retaining moisture, rapidly eliminating inflammations, resisting allergy, relieving itching, delaying aging, etc. The sandalwood essential oil can promote growth of skin cells and rapid recovery of wounds and scars and thus exerts elasticizing and astringing effects and is capable of balancing and softening skin, improving dryness and fading wrinkles; the sandalwood essential oil is especially applicable to maintenance of aged, dry and hydropenic skin and necks and beneficial for dry skin, hardened keratoderma, xerotic eczema, wounds, etc.; and the sandalwood essential oil enables skin to become soft and improves itching and inflammations of skin, facial blisters and furuncle, and infected wounds. The palmarosa essential oil is applicable to oily and hydropenic skin.
PURPOSE OF REVIEW: Sarcopenia, generally characterized by the age-related reduction in muscle strength, lean/muscle mass and functional ability, is also associated with reduced bone mass and strength and impaired brain health and function. One potential intervention which has received much 'hype' over the past few decades to countermeasure these negative consequences of biological aging is creatine monohydrate supplementation.
RECENT FINDINGS: From a skeletal muscle perspective, the combination of creatine monohydrate supplementation and resistance training provides 'hope' for older adults as it improves measures of lean mass, regional (limb) muscle thickness, upper- and lower-body muscle strength and functional ability. Further, there is some evidence that creatine (supplementation or habitual diet) provides a ray of 'hope' for improving some aspects of cognitive function. The majority of research suggests that creatine is more 'hype' than 'hope' for improving measures of bone mass in older adults. Creatine monohydrate supplementation provides some anti-sarcopenic benefits for older adults.
The invention relates to a drug delivery system comprising an oil-in-water microemulsion to improve the solubility and bioavailability of lipophilic active ingredient. The invention also provides a pharmaceutical composition containing magnolol microemulsion, and the use of magnolol and its micro-emulsion to prepare a drug for treating apoplexy. The drug delivery system comprises an active ingredient and a carrier system for forming an oil-in-water microemulsion. The carrier system includes water, oil and emulsifier, wherein the weight percentage of water is 5% to 60%, the weight percentage of oil is 5% to 80% and the weight percentage of emulsifier is 15% to 90% based on the total weight of the carrier system. The oil contains fatty acid oil and the emulsifier contains a surfactant and a cosurfactant, wherein the surfactant is a nonionic surfactant. The oil further contains oleic acid, triglyceride, olive oil, glycerol, <alpha>-linolenic acid (ALA), heneicosapentaenoic acid (HPA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), eicosatetraenoic acid (ETA), eicosatrienoic acid (ETE), linoleic acid, <gamma>-linolenic acid (GLA), arachidonic acid (AA) or any combination thereof. The surfactant includes Tween, and/or the co-surfactant includes propylene glycol, polyethylene glycol (PEG), diethylene glycol monoethyl ether, labrasol, ethoxylated hydrogenated castor oil, polyvinyl alcohol (PVA), or any combination thereof. The emulsifier contains Tween 80, 1,2-propylene glycol (1,2-PG), and polyethylene glycol 400 (PEG 400), wherein the content of Tween 80 is 5% to 60%, the content of 1,2-propylene glycol is 5% to 60% and the content of polyethylene glycol 400 is 5% to 60% based on the total amount of emulsifier. The active ingredient comprises any one or a combination of magnolol, curcumin or a medicinal salt thereof. The diameter of the droplets in the microemulsion ranges from 50 nm to 2500 nm. The viscosity of the microemulsion is 15 to 200 centipoise (cP). The drug loading for the active ingredient of the microemulsion is at least 10 mg/ml.
An electrocardiogram is a medical examination tool for measuring different patterns of heart blood flow circle either in the form of usual or non-invasive patterns. These patterns are useful for the identification of morbidity condition of the heart especially in certain conditions of heart abnormality and arrhythmia. Myocardial infarction (MI) is one of them that happened due to sudden blockage of blood by the cause of malfunction of heart. In electrocardiography (ECG) intensity of MI is highlighted on the basis of unusual patterns of T wave changes. Various studies have contributed for MI through T wave's classification, but more to the point of T wave has always attracted the ECG researchers. Methodology. This Study is primarily designed for proposing the combination of latest methods that are worked for the solutions of pre-defined research questions. Such solutions are designed in the form of the systematic review process (SLR) by following the Kitchen ham guidance. The literature survey is a two phase's process, at first phase collect the articles that were published in IEEE Xplore, Scopus, science direct and Springer from 2008 to 2023. It consist of steps; the first level is executed by filtrating the articles on the basis of keyword phase of title and abstract filter. Similarly, at two level the manuscripts are scanned through filter of eligibility criteria of articles selection. The last level belongs to the quality assessment of articles, in such level articles are rectified through evaluation of domain experts. Results. Finally, the selected articles are addressed with research questions and briefly discuss these selected state-of-the-art methods that are worked for the T wave classification. These address units behave as solutions to research problems that are highlighted in the form of research questions. Conclusion and future directions. During the survey process for these solutions, we got some critical observations in the form of gaps that reflected the other directions for researchers. In which feature engineering, different dependencies of ECG features and dimensional reduction of ECG for the better ECG analysis are reflection of future directions.
PURPOSE: The GARDE platform uses family history reported in the electronic health record (EHR) to systematically identify eligible patients for genetic testing for hereditary cancer syndromes. The goal of this study was to evaluate the change in effectiveness of GARDE to identify eligible individuals when more comprehensive family history data are provided, thus quantifying the impact of underdocumentation.
METHODS: A cohort of 133,764 patients at the University of Utah Health was analyzed with GARDE comparing identification rates using EHR data versus EHR plus data from a statewide population database, the Utah Population Database (UPDB).
RESULTS: Compared with EHR alone, EHR + UPDB increased the rate of individuals eligible for genetic testing from 4.1% to 9.2%. In the 44,692 individuals with the most comprehensive family history, eligibility more than quadrupled from 4.6% (EHR alone) to 19.3% (EHR + UPDB). The increase was significant across all demographics, but disparities still remained for historically marginalized minorities (9.2%-13.9% in non-White races compared with 19.7% in White races).
CONCLUSION: Augmenting EHR data with family history data from the UPDB substantially improved the detection of individuals eligible for genetic testing of hereditary cancer syndromes in all subgroups. This underscores the importance of improving methods for acquiring family history, in person or in silico. However, these increases did not ameliorate disparities. Continuous disparities are unlikely to be explained by incomplete family history alone and may also be because susceptibility genes, risk variants, and screening guidelines were discovered and developed largely in White races. Addressing disparities will require intentional data collection of family history in historically marginalized minorities and the promotion of genetic and risk assessment studies in more diverse populations to ensure equity and health care.
IVH occurs in about 40 percent of intracerebral hemorrhage cases and 15 percent of aneurysmal subarachnoid hemorrhage cases. Evidence supports a strong contribution of IVH to morbidity and mortality after cerebral hemorrhage. External ventricular drainage (EVD) is required clinical management; however, EVD via intraventricular catheter alone fails to prevent much of the morbidity and mortality of IVH. This study seeks to demonstrate the safety and efficacy of intraventricular thrombolysis, using rt-PA, as a method of removing this blood and altering morbidity and mortality. Patients will receive intraventricular injections of rt-PA or placebo every 12 hours. They will be followed prospectively with daily head CT scans during the acute-treatment phase and again between Days 28 and 32.

Completion date provided represents the completion date of the grant per OOPD records
A configuration system provides configuration information for electronic components and systems, particularly for consumer electronics components and systems. The configuration system may include one or more of the following: a system configurator, a wiring configurator, and a placement configurator. An integrated configuration system includes two or all of the configurators. The integrated configuration system combines content, guidance, and commerce, uniquely tailored to the needs of consumers in a particular field of electronics. In a preferred embodiment, consumers enter preferences relating to audiovisual products and receive personalized recommendations for components available for purchase. The wiring configurator generates customized wiring diagrams for selected components, to identify required interconnection devices, and to ease the task of interconnecting the components. The placement configurator, or room configurator, allows the consumer to enter room dimensions, furniture location and other relevant information, and provides guidance for optimal audiovisual product selection and placement. A database of audiovisual componant information provides component specifications, product reviews, reliability and repair ratings, compatibility and interaction issues, and other information that assists the consumer in the component selection process, and also includes detailed technical information to assist the consumer in the installation process, including providing wiring diagrams for each combination of products. The database is provided in searchable form that can be used in connection with templates or other search techniques to enable a user to specify one or more preferences and be provided information about audiovisual products that are available that satisfy the identified preferences.
PURPOSE:The titled drug containing a prostaglandin I2 analog compound. CONSTITUTION:A drug containing a compound expressed by formula I (R<1> is H, 1-12C alkyl, 4-7C cycloalkyl, etc.; A is pentyl, cyclopentyl, etc.) or a nontoxic salt of the acid or a cyclodextrin clathrate compound thereof as an active constituent, and having ameliorant action on circulation and antiulcer action. The agent has powerful inhibitory action on blood platelet agglutination, hypotensive action, vasodilator action and antiulcer action, and low toxicity. The agent can be orally or parenterally administered, and the dose thereof is 0.1- 100mg/time, preferably 1mug-1mg/time, and preferably administered one - several times a day. The compound expressed by formula I is obtained by reducing a compound expressed by formula II (R<1>' is 1-2C alkyl, 4-7C cycloalkyl, etc.; R<2> is a protecting group of OH), removing the protecting group from the reduction product and hydrolyzing the resultant product, etc.
PURPOSE:To effectively and safely protect against the oxygen toxicity and phototoxicity caused by ultraviolet rays. CONSTITUTION:A compd. of formula 1 [wherein R1 and R2 are each independently H, an aliph. satd. or unsatd. linear or branched 1-22C hydrocarbon group, acyl, or amidino; R3 is H or -COOR4 (wherein R4 is H, an aliph. satd. or unsatd. linear or branched 1-22C hydrocarbon group, or an alkali or alkaline earth metal); and n is or 1] is used as the effective component of an active-oxygen scavenger, an external preparation for skin, and a preventive and/or therapeutic preparation for disease caused by active oxygen or free radical.
PURPOSE:To obtain ultraviolet ray-blocking powder consisting of a globular silica containing a specific ultraviolet ray-reflecting substance and having good lubricating property and water repellency and to obtain a cosmetic containing this powder, having good slip in coating, smoothness on skin, good adhesiveness to skin and free from messy makeup. CONSTITUTION:The surface of a ultraviolet ray-reflecting substance (especially preferably titanium oxide, zinc oxide, cerium oxide, etc.) is treated by mixing a plate-like N-lauroyl-L-lysin with the ultraviolet reflecting substance under stirring using a mixing and stirring apparatus such as Henschel mixer. A globular silica containing this surface-treated substance provides the objective ultraviolet ray-blocking powder. This powder is included in cosmetic to provide the objective ultraviolet ray-blocking cosmetic having good slip in coating, smoothness on skin, adhesiveness to skin as well as good water repellency and water resistance, excellent in effect for preventing disorder of cosmetic and having good touch feeling. The average particle diameter of the globular silica is preferably 1-50mum. The plate-like N-lauroyl-L-lysin is obtained by heating and dehydrating, e.g. L-lysin and lauric acid.